Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 11/20 | 0.37 |
| ▸ | SSTR1 | P30872 | 8/20 | 0.37 |
| ▸ | DHODH | Q02127 | 1/20 | 0.35 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.35 |
| ▸ | P2RY14 | Q15391 | 2/20 | 0.35 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.35 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.34 |
| ▸ | ABL1 | P00519 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30761883 | 1.00 | SSTR4 (0.37) | SSTR4SSTR1DHODHP2RY1P2RY14 | |
| SCHEMBL30672649 | 0.85 | ENPP2 (0.34) | SSTR4ENPP2 | |
| SCHEMBL896649 | 0.85 | ENPP2 (0.34) | SSTR4ENPP2 | |
| SCHEMBL12097746 | 0.81 | SCN9A (0.41) | SSTR4SSTR1 | |
| SCHEMBL29489857 | 0.79 | ENPP2 (0.47) | ENPP2 | |
| SCHEMBL4794 | 0.79 | ENPP2 (0.47) | ENPP2 | |
| SCHEMBL27194698 | 0.78 | LIPE (0.36) | ENPP2 | |
| SCHEMBL29057683 | 0.77 | TRPV4 (0.36) | ENPP2 | |
| Water SCHEMBL29953222 | 0.77 | ENPP2 (0.45) | ENPP2 | |
| Water SCHEMBL1543573 | 0.77 | ENPP2 (0.45) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-10-17 | — | — | US | disclosed |
| US-11958865-B1 | Leucine-rich repeat kinase 2 (LRRK2) inhibitors | H. LUNDBECK A/S (DK) | 2024-04-16 | — | — | US | disclosed |
| WO-2024056775-A1 | MACROCYCLIC LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | H. LUNDBECK A/S (DK) | 2024-03-21 | — | — | WO | disclosed |
| WO-2008021960-A2 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343741-A1 | LEUCINE-RICH REPEAT KINASE 2 (LRRK2) INHIBITORS | LRRK2, PARK7, PINK1 | SSTR4 4764/4885SSTR1 4719/4885DHODH 3852/4885 |
| US-11958865-B1 | Leucine-rich repeat kinase 2 (LRRK2) inhibitors | LRRK2, PARK7, PINK1 | SSTR4 4764/4885SSTR1 4719/4885DHODH 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.